Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States.
Rhodes NJ, Dairem A, Moore WJ, Shah A, Postelnick MJ, Badowski ME, Michienzi SM, Borkowski JL, Polisetty RS, Fong K, Spivak ES, Beardsley JR, Hale CM, Pallotta AM, Srinivas P, Schulz LT.
Rhodes NJ, et al. Among authors: beardsley jr.
Am J Health Syst Pharm. 2021 Mar 18;78(7):568-577. doi: 10.1093/ajhp/zxaa426.
Am J Health Syst Pharm. 2021.
PMID: 33537767
Free PMC article.